Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
_256_384.jpg)
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Renalyx will continue operating as an independent unit within the group
Subscribe To Our Newsletter & Stay Updated
